Kira Pharmaceuticals’ $53.5 Million Series B+ Financing


Brown Rudnick LLP advised RA Capital Management on the deal.

Kira Pharmaceuticals announced its $53.5-million Series B+ financing to advance the LOGIC drug discovery platform.

Kira Pharmaceuticals is a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases.

The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing. RA Capital Management is a leading investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics.

The Brown Rudnick deal team was led by Adam Schoen (Picture) and Robert Ruh.

Involved fees earner: Robert Ruh III – Brown Rudnick; Adam Schoen – Brown Rudnick;

Law Firms: Brown Rudnick;

Clients: RA Capital Management;

Avatar

Author: Ambrogio Visconti